Pfizer's Selzentry granted full US approval

8 December 2008

The US Food and Drug Administration has granted world drug giant Pfizer's Selzentry (maraviroc) full approval for use in treatment-experienced adults with CCR5-tropic HIV-1 in combination with other antiretrovirals.

Full approval removes restrictions on promotion and distribution that apply to conditionally-cleared medicines. The viral entry blocker was originally granted accelerated conditional approval in August 2007 based on 24-week data from Phase III studies and was given the nod by an FDA panel a few months before (Marketletter April 30, 2007).

Pfizer says that the FDA's Antiviral Drugs Advisory Committee voted unanimously to recommend the approval of its CCR5 antagonist maraviroc for use along with other antiretrovirals for treatment-experienced patients infected with CCR5-tropic HIV-1.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight